Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Venezuela Hits Dr. Reddy’s Profit, But Indicators Brighter

This article was originally published in PharmAsia News

Executive Summary

Indian generic drug heavyweight Dr. Reddy’s quarterly net profit has tumbled nearly 90% on an exceptional charge involving a $65m write-down on receipts due from its Venezuelan subsidiary but improved financial performance indicators have cheered investors.


Related Content

Dr Reddy's Slumps In Q1 But Will Pressures Ease Soon?
India Q1 Results Preview: Exclusivity, Compliance Are Key Talking Points


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts